ESTRO 2025 - Abstract Book

S902

Clinical - Haematology

ESTRO 2025

Conclusion: Repeated hematopoietic stem cell transplantation with TBI may be effective in some cases. Chronic liver dysfunction was not observed; however, serious adverse events in the kidneys and lungs should be monitored carefully.

Keywords: total body irradiation, re-irradiation

2843

Proffered Paper Updated results of a comprehensive prospective protocol of radiotherapy bridging and consolidation for CAR-T in large B-cell lymphoma (RESTART) Stella Bouziana 1,2 , George Mikhaeel 3,2 , Christianne Bourlon 1 , Deborah Springell 4 , Claire Roddie 4 , Jessica Brady 3 , Madson Correia De Farias 1 , Robin Sanderson 1 , Reuben Benjamin 1,2 , Angela Hwang 4 , Michael Northend 4 , Sachin Kamat 5 , Kenneth Courtney 5 , Piers Patten 1,2 , Emil Kumar 1 , Prudence Hardefeldt 1 , Deborah Yallop 1 , Georgios Ntentas 6 , Karimali Keshwani 7 , Suganya Sivabalasingham 7 , Andrea Kuhnl 1 1 Department of Haematology, King's College Hospital, London, United Kingdom. 2 School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom. 3 Department of Clinical Oncology, Guy´s Cancer Centre, Guy´s and St Thomas´ Hospital, London, United Kingdom. 4 Department of Haematology, University College London Hospital, London, United Kingdom. 5 Department of Nuclear Medicine, King's College Hospital, London, United Kingdom. 6 Department of Medical Physics and Clinical Engineering, Guy´s and St Thomas´ Hospital, London, United Kingdom. 7 Department of Clinical Oncology, University College London Hospital, London, United Kingdom Purpose/Objective: We initiated a prospective protocol (RESTART) in LBCL patients treated with anti-CD19 CAR-T to standardise, promote and optimize radiotherapy (RT) as bridging, including advanced stage, and introduce early consolidation RT (cRT) based on predefined criteria while using CAR-T-sparing RT techniques. We present the updated results of the patients treated on the RESTART protocol. Material/Methods: We prospectively included LBCL patients approved for anti-CD19 CAR-T as second or third-line across two large UK CAR-T centres from September 2019 until May 2024.